Similar articles

• Use of vaccinia virus vectors for development of AIDS vaccines.

  Moss B. Moss B. AIDS. 1988;2 Suppl 1:S103-5. doi: 10.1097/00002030-198800001-00015. AIDS. 1988. PMID: 3147660 Review. No abstract available.
• Multiple cytotoxic effector cells are induced by infection with the human immunodeficiency virus.

  Rivière Y, Tanneau-Salvadori F, Regnault A, Lopez O, Sansonetti P, Guy B, Kieny MP, Fournel JJ, Montagnier L. Rivière Y, et al. Res Immunol. 1989 Jan;140(1):110-5; discussion 121. doi: 10.1016/0923-2494(89)90015-1. Res Immunol. 1989. PMID: 2657908 Review. No abstract available.
• Human trials of experimental AIDS vaccines: recombinant envelope proteins.

  Snart RS. Snart RS. AIDS. 1988;2 Suppl 1:S107-11. doi: 10.1097/00002030-198800001-00016. AIDS. 1988. PMID: 2906544 Clinical Trial. No abstract available.
• Cytotoxic T-cell recognition of HIV proteins and peptides.

  Nixon DF, McMichael AJ. Nixon DF, et al. AIDS. 1991 Sep;5(9):1049-59. AIDS. 1991. PMID: 1718319 No abstract available.
• Predictions of linear T-cell and B-cell epitopes in proteins encoded by HIV-1, HIV-2 and SIVMAC and the conservation of these sites between strains.

  Zvelebil MJ, Sternberg MJ, Cookson J, Coates AR. Zvelebil MJ, et al. FEBS Lett. 1988 Dec 19;242(1):9-21. doi: 10.1016/0014-5793(88)80976-1. FEBS Lett. 1988. PMID: 2462515